5 March 2021
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Director dealing
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, has been notified that Richard Moulson, Chief Financial Officer of the Company, has purchased 3,787 ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") at a purchase price of 8 pence per Ordinary Share, as part of the Open Offer in the recent Fundraise. Following this purchase, Richard Moulson holds a total of 45,454 Ordinary Shares, representing approximately 0.02 per cent. of the Company's issued share capital.
Enquiries:
| Evgen Pharma plc Barry Clare, Chairman Dr Huw Jones, CEO Richard Moulson, CFO
| Via Walbrook |
| finnCap Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane / Sunila de Silva (ECM)
| +44 (0) 20 7220 0500 |
| Walbrook PR Paul McManus/ Anna Dunphy
| +44 (0)20 7933 87870 or evgen@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 741 001
|
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):
| 1. | Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') | |||||
| a) | Name | Richard Moulson | ||||
| 2. | Reason for notification | |||||
| b) | Position / status | CFO | ||||
| c) | Initial notification / amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| b) | Name | Evgen Pharma plc | ||||
| c) | LEI | 213800NO3E6TSTQO8K20 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code
| ordinary shares of 0.25p each
GB00BSVYN304 | ||||
| b) | Nature of the transaction | Acquisition of shares pursuant to the Open Offer | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | As above | ||||
| e) | Date of the transaction | 3 March 2021 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
